[go: up one dir, main page]

MX2015011393A - Poli(beta-amino esteres) modificados para suministro de farmaco. - Google Patents

Poli(beta-amino esteres) modificados para suministro de farmaco.

Info

Publication number
MX2015011393A
MX2015011393A MX2015011393A MX2015011393A MX2015011393A MX 2015011393 A MX2015011393 A MX 2015011393A MX 2015011393 A MX2015011393 A MX 2015011393A MX 2015011393 A MX2015011393 A MX 2015011393A MX 2015011393 A MX2015011393 A MX 2015011393A
Authority
MX
Mexico
Prior art keywords
polymers
beta
drug delivery
amino ester
modified poly
Prior art date
Application number
MX2015011393A
Other languages
English (en)
Other versions
MX364396B (es
Inventor
Salvador Borrós Gómez
Victor Ramos Pérez
Pere Dosta Pons
Nathaly Verónica Segovia Ramos
Original Assignee
Inst Químic De Sarrià Cets Fundació Privada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Químic De Sarrià Cets Fundació Privada filed Critical Inst Químic De Sarrià Cets Fundació Privada
Publication of MX2015011393A publication Critical patent/MX2015011393A/es
Publication of MX364396B publication Critical patent/MX364396B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a polímeros que son polo (beta-amino ésteres) (PBAEs) modificados con al menos un oligopéptido. Los polímeros pueden ser usados en cualquier campo donde los polímeros han encontrado ser útiles, que incluyen en campos médicos, particularmente en suministro de fármaco. Los polímeros son particularmente útiles en el suministro de un polinucleótido tal como ADN, ARN y siARN, una molécula pequeña o una proteína. También se describen composiciones que comprenden tales polímeros y un agente activo, métodos para encapsular un agente en una matriz de tales polímeros, y tales polímeros y composiciones para uso en medicina.
MX2015011393A 2013-03-08 2014-03-10 Poli(beta-amino esteres) modificados para suministro de farmaco. MX364396B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1304245.2A GB201304245D0 (en) 2013-03-08 2013-03-08 Chemical compounds
PCT/IB2014/059594 WO2014136100A1 (en) 2013-03-08 2014-03-10 Modified poly(beta-amino ester)s for drug delivery

Publications (2)

Publication Number Publication Date
MX2015011393A true MX2015011393A (es) 2016-06-06
MX364396B MX364396B (es) 2019-04-25

Family

ID=48189627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011393A MX364396B (es) 2013-03-08 2014-03-10 Poli(beta-amino esteres) modificados para suministro de farmaco.

Country Status (17)

Country Link
US (2) US20160038598A1 (es)
EP (1) EP2964244B1 (es)
JP (1) JP6473421B2 (es)
KR (1) KR102191195B1 (es)
CN (1) CN105324120B (es)
AR (1) AR095081A1 (es)
AU (1) AU2014224219B2 (es)
BR (1) BR112015021709B8 (es)
CA (1) CA2903663C (es)
DK (1) DK2964244T3 (es)
ES (1) ES2781965T3 (es)
GB (1) GB201304245D0 (es)
MX (1) MX364396B (es)
PL (1) PL2964244T3 (es)
RU (1) RU2015142677A (es)
TW (1) TW201446269A (es)
WO (1) WO2014136100A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US10174289B2 (en) 2014-05-28 2019-01-08 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
GB201501025D0 (en) * 2015-01-21 2015-03-04 Sagetis Biotech Sl Chemical compounds
WO2017112704A1 (en) * 2015-12-23 2017-06-29 Viking Scientific, Inc. Hydrogel prodrug for treatment
CN105535994B (zh) * 2015-12-25 2018-01-19 华中科技大学同济医学院附属同济医院 一种治疗hpv感染的纳米粒制剂及其制备方法
CA3016641A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
KR102546194B1 (ko) 2016-11-04 2023-06-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
WO2018106628A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
CN106727313B (zh) * 2017-01-06 2020-04-10 国家纳米科学中心 一种载药聚合物纳米胶束及其制备方法和应用
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
GB201708203D0 (en) * 2017-05-22 2017-07-05 Sagetis Biotech Sl Chemical compounds
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
WO2019084229A1 (en) 2017-10-27 2019-05-02 Massachusetts Institute Of Technology Poly (beta-amino esters) and uses thereof
WO2019090045A1 (en) * 2017-11-03 2019-05-09 Massachusetts Institute Of Technology Gene delivery carrier
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
AU2019213290A1 (en) * 2018-01-17 2020-08-06 Ixaka France SAS Polymer-encapsulated viral vectors for genetic therapy
WO2020023245A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
SG11202102431YA (en) 2018-09-12 2021-04-29 Childrens Hospital Med Ct Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
CA3141729A1 (en) * 2019-05-31 2020-12-03 Children's Hospital Medical Center Polymer based cellular labeling, barcoding and assembly
EP3976066A4 (en) 2019-05-31 2023-06-28 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CA3151983A1 (en) * 2019-09-21 2021-03-25 Ozgul TEZGEL Dmso-free synthesis of oligopeptide-modified poly(beta-amino ester)s and their use in nanoparticle delivery systems
AU2020383821A1 (en) 2019-11-15 2022-06-23 Ixaka France Polymer-encapsulated viral vectors for in vivo genetic therapy
MX2022011969A (es) * 2020-03-27 2023-01-16 Ixaka France Poli(beta-amino éster (es)) dirigidos.
WO2021255262A1 (en) 2020-06-19 2021-12-23 Sylentis Sau siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
CN116472303A (zh) * 2020-11-19 2023-07-21 恩盖普有限公司 具有提高的降解性的聚丙烯酸酯和聚(β-酯)胶囊
EP4015634A1 (en) 2020-12-15 2022-06-22 Sylentis, S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
WO2022192176A1 (en) 2021-03-09 2022-09-15 Massachusetts Institute Of Technology Branched poly(-amino esters) for the delivery of nucleic acids
WO2023006651A1 (en) * 2021-07-26 2023-02-02 Institut Quimic De Sarria Cets Fundacio Privada Covalently coated adeno-associated virus vector for its use in gene therapy
EP4166594A1 (en) 2021-10-14 2023-04-19 Institut Químic de Sarrià CETS Fundació Privada Zwitterionic functionalized poly(beta-aminoester) polymers and uses thereof
WO2025067539A1 (zh) * 2023-09-28 2025-04-03 上海科技大学 一种聚β氨基脂化合物、其组合物和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1117720A4 (en) * 1998-07-13 2001-11-14 Expression Genetics Inc POLYESTER POLY-L-LYSINE ANALOG USED AS A BIODEGRADABLE SOLUBLE GENE CONVEYOR
US7427394B2 (en) * 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
ATE419842T1 (de) * 2004-09-14 2009-01-15 Nanodel Technologies Gmbh Abgabevehikel mit nanoteilchen
WO2008011561A2 (en) * 2006-07-21 2008-01-24 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
US20100196492A1 (en) * 2007-03-08 2010-08-05 Green Jordan J Electrostatic coating of particles for drug delivery
US9717694B2 (en) 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
GB0913442D0 (en) * 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US20140294909A1 (en) * 2011-10-13 2014-10-02 The Johns Hopkins University Nanocomposites of gold and polymers

Also Published As

Publication number Publication date
BR112015021709B1 (pt) 2022-03-03
EP2964244B1 (en) 2020-01-08
CA2903663A1 (en) 2014-09-12
BR112015021709B8 (pt) 2022-04-05
ES2781965T3 (es) 2020-09-09
CA2903663C (en) 2022-08-30
JP6473421B2 (ja) 2019-02-20
EP2964244A1 (en) 2016-01-13
MX364396B (es) 2019-04-25
RU2015142677A (ru) 2017-04-13
CN105324120A (zh) 2016-02-10
DK2964244T3 (da) 2020-04-06
US20160038598A1 (en) 2016-02-11
AR095081A1 (es) 2015-09-16
CN105324120B (zh) 2021-04-02
KR20150135334A (ko) 2015-12-02
TW201446269A (zh) 2014-12-16
AU2014224219B2 (en) 2018-12-13
AU2014224219A1 (en) 2015-09-24
WO2014136100A1 (en) 2014-09-12
GB201304245D0 (en) 2013-04-24
BR112015021709A2 (pt) 2017-07-18
KR102191195B1 (ko) 2020-12-16
JP2016511316A (ja) 2016-04-14
US20180250410A1 (en) 2018-09-06
PL2964244T3 (pl) 2020-08-24

Similar Documents

Publication Publication Date Title
MX364396B (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
CA2863964C (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
BR112015015319A2 (pt) composições de nanopartícula de albumina e paclitaxel
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
MX2018003306A (es) Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
WO2015095624A3 (en) Drug mixing and delivery system and method
MX2021008464A (es) Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX2013003892A (es) Composicion farmaceutica liquida para el suministro de ingredientes activos.
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2013028942A8 (en) Targeting microbubbles
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
MD20160079A2 (ro) Sistem de livrare a medicamentului
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
IN2015KN00005A (es)
PH12018500449A1 (en) Polymeric bile acid nanocompositions targeting the pancreas and colon
WO2015031771A3 (en) Administration of kynurenine depleting enzymes for tumor therapy
MX2015012060A (es) Forma de dosificacion solida de disuasivo del abuso para liberacion inmediata con marca funcional.
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
AR105223A1 (es) Compuestos químicos
MX2014014662A (es) Manufactura de degarelix.
GB2528421A (en) Methods and processes for application of drug delivery polymeric coatings
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
EP3725331A4 (en) MODIFIED CARBON NANOMATERIAL, NANOAGGREGATE, VECTOR OF SUBSTANCE DELIVERY, AND PHARMACEUTICAL COMPOSITION
MX375186B (es) Composiciones de anfetamina transdérmica estable y métodos de fabricación.

Legal Events

Date Code Title Description
FG Grant or registration